Drugs / 18F-PF974
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07169630 | Oct 2026 → Apr 2029 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-PF974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07169630 ↗ |
| Modality | Diagnostic / imaging agent | “new radiotracer” NCT07169630 ↗ |
| Route | Intravenous | “Injected IV followed by PET scanning” NCT07169630 ↗ |
| Target | PDE4B | “PDE4B radioligand binding” NCT07169630 ↗ |